SP2509 ≥95%

Supplier: ADIPOGEN CORP MS

SYN-1212-M010 SYN-1212-M001 SYN-1212-M005
102979-856EA 373.85 USD
102979-856 102979-858 102979-854
SP2509 ≥95%
SP2509

LSD1 is a promising target for cancer therapy. Epigenetic control of histone methylation is frequently associated with oncogenesis and LSD1 is overexpressed in many types of cancer. siRNA knockdown of LSD1 has been shown to suppress growth of cancer cells. SP-2528 is a selective and reversible LSD1 inhibitor with an IC(50) of 10nM. SP-2528 demonstrates a high specificity for LSD1, with no effect on MAOi.

Formula: C₁₉H₂₀ClN₃O₅S
MW: 437.9 g/mol
Storage Temperature: Freezer
MDL Number: MFCD28348370
CAS Number: 1423715-09-6

Order Now

Specification Test Results

Purity 95%
Appearance/Color Solid.
Solubility Soluble in DMSO.

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR